Literature DB >> 24168322

Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt.

Palash Sanphui1, Srinu Tothadi, Somnath Ganguly, Gautam R Desiraju.   

Abstract

Sildenafil is a drug used to treat erectile dysfunction and pulmonary arterial hypertension. Because of poor aqueous solubility of the drug, the citrate salt, with improved solubility and pharmacokinetics, has been marketed. However, the citrate salt requires an hour to reach its peak plasma concentration. Thus, to improve solubility and bioavailability characteristics, cocrystals and salts of the drug have been prepared by treating aliphatic dicarboxylic acids with sildenafil; the N-methylated piperazine of the drug molecule interacts with the carboxyl group of the acid to form a heterosynthon. Salts are formed with oxalic and fumaric acid; salt monoanions are formed with succinic and glutaric acid. Sildenafil forms cocrystals with longer chain dicarboxylic acids such as adipic, pimelic, suberic, and sebacic acids. Auxiliary stabilization via C-H···O interactions is also present in these cocrystals and salts. Solubility experiments of sildenafil cocrystal/salts were carried out in 0.1N HCl aqueous medium and compared with the solubility of the citrate salt. The glutarate salt and pimelic acid cocrystal dissolve faster than the citrate salt in a two hour dissolution experiment. The glutarate salt exhibits improved solubility (3.2-fold) compared to the citrate salt in water. Solubilities of the binary salts follow an inverse correlation with their melting points, while the solubilities of the cocrystals follow solubilities of the coformer. Pharmacokinetic studies on rats showed that the glutarate salt exhibits doubled plasma AUC values in a single dose within an hour compared to the citrate salt. The high solubility of glutaric acid, in part originating from the strained conformation of the molecule and its high permeability, may be the reason for higher plasma levels of the drug.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24168322     DOI: 10.1021/mp400516b

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.

Authors:  Dipak Dilip Gadade; Sanjay Sudhakar Pekamwar
Journal:  Adv Pharm Bull       Date:  2016-12-22

2.  Self-nanoemulsifying formulation for oral delivery of sildenafil: effect on physicochemical attributes and in vivo pharmacokinetics.

Authors:  Sanyog Jain; Narinder Kumar; Reena Sharma; Rohan Ghadi; Tushar Date; Nallamothu Bhargavi; Dasharath Chaudhari; Sameer S Katiyar
Journal:  Drug Deliv Transl Res       Date:  2022-10-12       Impact factor: 5.671

Review 3.  Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.

Authors:  Andreas Ouranidis; Anastasia Tsiaxerli; Elisavet Vardaka; Catherine K Markopoulou; Constantinos K Zacharis; Ioannis Nicolaou; Dimitris Hatzichristou; Anna-Bettina Haidich; Nikolaos Kostomitsopoulos; Kyriakos Kachrimanis
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-15

Review 4.  Solubility Enhancement of Antidiabetic Drugs Using a Co-Crystallization Approach.

Authors:  Eustina Batisai
Journal:  ChemistryOpen       Date:  2021-12       Impact factor: 2.911

5.  Impact of the Dicarboxylic Acid Chain Length on Intermolecular Interactions with Lidocaine.

Authors:  Julija Zotova; Brendan Twamley; Lidia Tajber
Journal:  Mol Pharm       Date:  2022-07-19       Impact factor: 5.364

6.  Why sildenafil and sildenafil citrate monohydrate crystals are not stable?

Authors:  Somchai Sawatdee; Chaveng Pakawatchai; Kwanjai Nitichai; Teerapol Srichana; Hirihattaya Phetmung
Journal:  Saudi Pharm J       Date:  2015-01-24       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.